Patient-Friendly Explanation

Amycretin is a new investigational weight-management medication taken by mouth that targets two hormones involved in appetite and blood-sugar control. Early studies suggest it can produce significant weight loss. It is still in clinical trials and is not yet widely available, but it represents the next generation of weight-loss treatments.

Clinical Definition

Amycretin is an investigational oral co-agonist targeting both the GLP-1 and amylin receptors, developed for obesity and type 2 diabetes. By combining incretin and amylin pathways, it aims to enhance appetite suppression, delay gastric emptying, and improve glycaemic control. Early-phase trial data have reported double-digit percentage weight loss, with further development and regulatory evaluation ongoing.

Why It Matters

Amycretin illustrates the rapid evolution of pharmacotherapy toward oral, dual-pathway agents that may one day offer the efficacy of injectable treatments in tablet form. NuLifeCare Singapore follows emerging obesity pharmacotherapy closely so patients have access to the most appropriate, evidence-based options as they become available.